Personalised Medicine in Pre-diabetes and Early Type 2 Diabetes
Status:
Recruiting
Trial end date:
2023-12-23
Target enrollment:
Participant gender:
Summary
Prediabetes is a common condition in overweight individuals affecting approximately 35% of
American adults and 30% of Australian adults. Like diabetes, prediabetes is a serious risk
factor for cardiovascular disease, eye, kidney and liver disease, and some types of cancer.
Appropriate blood glucose control is crucial in preventing pre-diabetes complications and
onset of diabetes, yet clinical practice, backed by randomised trials, reports that many
patients treated with standard dietary guidelines or with the first-line treatment of
diabetes patients, metformin, do not improve blood glucose control sufficiently.
The overarching goal of the present project is to improve the efficacy of metformin
mono-therapy in pre-diabetes and early type 2 diabetes.